How do you approach ovarian function suppression in premenopausal women with HR+/HER2-, node negative breast cancer and intermediate OncoType dx scores (11-25) who received chemotherapy?

The SOFT/TEXT data showed that the patients who benefited from ovarian suppression + endocrine therapy were those who were <35 years old or those who had prior chemotherapy (essentially those patients who were deemed to have high risk disease). The TAILORx study demonstrated that patients with recur...